| Literature DB >> 35547099 |
Ricardo Issler Unfried1,2, Luciana Maria Fontanari Krause2, Helen Minussi Cezimbra3, Liliane Souto Pacheco4,3, João Alberto Larangeira1, Tiango Aguiar Ribeiro1,2,4,5,6.
Abstract
Purpose: Prosthetic joint infection (PJI) is a devastating complication that can affect hip arthroplasty. Its treatment is extremely difficult, and issues regarding the optimal treatment remain unanswered. This study intended to show the effectiveness of the one-stage treatment of PJI. Materials andEntities:
Keywords: Hip; Xenograft; arthroplasty; bone graft; infected arthroplasty; lyophilized bovine xenograft; one-stage exchange; one-stage revision; one-stage surgical time; periprosthetic joint infection; replacement; total hip arthroplasty
Year: 2022 PMID: 35547099 PMCID: PMC9081729 DOI: 10.1177/11795441221090344
Source DB: PubMed Journal: Clin Med Insights Arthritis Musculoskelet Disord ISSN: 1179-5441
Definition of periprosthetic joint infection according to the International Consensus Group.
| Major criteria (at least one of the following) | Decision | |||
|---|---|---|---|---|
| Two positive cultures of the same organisms | Infected | |||
| A sinus tract with evidence of communication to the joint or visualization of the prosthesis | ||||
| Minor criteria | Score | Decision | ||
| Serum | Elevated CRP or D-Dimer | 2 | ⩾6 infected | |
| Elevated ESR | 1 | |||
| Synovial | Elevated synovial WBC or LE | 3 | 2-5 possibly infected
| |
| Positive alpha-defensin | 3 | |||
| Elevated synovial PMN (%) | 2 | 0-1 not infected | ||
| Elevated synovial CRP | 1 | |||
| Inconclusive pre-op score or dry tap
| Score | Decision | ||
| Intraoperative diagnoses | Preoperative score | – | ⩾6 infected | |
| Positive histology | 3 | 4-5 inconclusive
| ||
| Positive purulence | 3 | |||
| Single positive culture | 2 | ⩽3 not infected | ||
| Marker | Chronic (>90 days) | Acute (<90 days) | ||
| Serum CRP (mg/dL) | 1.0 | 10 | ||
| Serum D-dimer (ng/mL) | 860 | 860
| ||
| Serum ESR (mm/h) | 30 | – | ||
| Synovial WBC count (cells/mL) | 3000 | 10 000 | ||
| Synovial PMN (%) | 80 | 90 | ||
| Synovial CRP (mg/L) | 6.9 | 6.9 | ||
| Synovial alpha-defensin (signal-to-cutoff ratio) | 1.0 | 1.0 | ||
Source: Reprinted from Parvizi et al , pp. 1312 and 1313, Copyright (2018), with permission from Elsevier.
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LE, leukocyte esterase; PMN, polymorphonuclear; WBC, white blood cell.
This is an adaptation of the Musculoskeletal Infection Society Definition of PJI. New scoring based definition for periprosthetic joint infection (PJI). Proceed with caution in: adverse local tissue reaction, crystal deposition disease, slow growing organisms.
For patients with inconclusive minor criteria, operative criteria can also be used to fulfill definition for PJI.
Consider further molecular diagnostics such as next-generation sequencing.
Further studies are needed to validate a specific threshold.
Figure 1.Flowchart.
PJI indicates periprosthetic joint infection, DAIR indicates debridement, antibiotics and implant retention.
Figure 2.Femoral osteotomy: (1) acetabulum; (2) top of the greater trochanter; (3) gluteus medius and minimus muscles; (4) distal insertion of the gluteus maximus; (5) vastus lateralis muscle; (6) lateral osteotomy performed on the femur, located 1.5-2 cm below the line of the lesser trochanter toward the diaphysis and did not exceed 1/3 of the femoral circumference; (7) cementless femoral component.
Population characteristics.
| Characteristics | |
|---|---|
| Age [years] (mean [SD] [CI] | 69.83 (9.76) (64.98-74.69) |
| GRAM-negative | 82 (0) (0) |
| GRAM-positive | 68.86 (8.91) (63.71-74) |
| GRAM-negative e-positive | 70.33 (14.57) (34.14-106.53) |
| Time from first arthroplasty to revision surgery [months] (mean [SD] [CI]) | 45.06 (45.18) (22.6-67.53) |
| GRAM-negative | 0.46 (0) |
| GRAM-positive | 53.78 (47.07) (26.60-80.96) |
| GRAM-negative e-positive | 19.23 (20.54) (-31.80-70.27) |
| Intrahospital stay [weeks] (median [IQR]) | 6 (6-9.5) |
| Comorbidity (n, %) | |
| Systemic arterial hypertension | 13 (72) |
| Ischemic heart disease | 3 (17) |
| Diabetes | 13 (72) |
| Ischemic cerebrovascular accident | 2 (11) |
| Kidney disease | 1 (6) |
| Lung disease (COPD) | 1 (6) |
| Social factors (n, %) | |
| Alcoholism | 1 (6) |
| Smoking | 5 (28) |
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SD, standard deviation.
Results of laboratory exams throughout treatment.
| Exam | Preoperative | 1 week | 2 weeks | 3 weeks | 4 weeks | 8 weeks | 16 weeks | 24 weeks | 48 weeks | 72 weeks | 96 weeks |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± standard deviation | |||||||||||
| Leukocyte | 7765.72 ± 3038.75 | 8929.44 ± 3447.92 | 9082.78 ± 3906.48 | 6972.35 ± 2776.01 | 7470.59 ± 3227.72 | 6628.19 ± 930.12 | 5797.73 ± 1766.00 | 5965.33 ± 2487.65 | 6256.43 ± 1024.89 | 6016.77 ± 830.64 | 6345.78 ± 1353.62 |
| Neutrophils (% of leukocyte) | 56.21 ± 16.96 | 62.64 ± 19.20 | 62.33 ± 10.37 | 56.36 ± 8.05 | 55.911 ± 11.15 | 56.13 ± 11.50 | 53.11 ± 9.42 | 53.71 ± 9.39 | 55.66 ± 7.56 | 51.41 ± 7.70 | 51.48 ± 9.58 |
| Band neutrophils (% of leukocyte) | 2.0 ± 2.4 | 6.22 ± 15.37 | 2.56 ± 3.63 | 2.53 ± 3.50 | 2.12 ± 3.22 | 2.69 ± 6.59 | 1.0 ± 1.25 | 0.53 ± 0.74 | 0.64 ± 0.93 | 0.85 ± 1.07 | 0.89 ± 1.05 |
| Lymphocytes (% of leukocyte) | 28.42 ± 13.63 | 18.74 ± 8.12 | 21.06 ± 8.65 | 23.64 ± 8.19 | 22.82 ± 7.99 | 24.51 ± 10.07 | 28.00 ± 11.31 | 24.37 ± 6.36 | 22.26 ± 8.57 | 24.21 ± 9.16 | 23.52 ± 11.40 |
| Platelets (cells/mm3) | 264 611.11 ± 78 182.40 | 260 444.44 ± 57 757.32 | 343 222.22 ± 83 058.84 | 371 352.94 ± 11 3131.53 | 283 941.18 ± 68 965.09 | 239 062.50 ± 46 401.82 | 261 066.67 ± 48 819.59 | 245 133.33 ± 25 447.05 | 240 142.86 ± 32 891.10 | 247 846.15 ± 50 578.07 | 258 888.89 ± 47 157.83 |
| Creatinine (mg/dL) | 1.15 ± 1.09 | 090 ± 0.29 | 0.86 ± 0.30 | 0.89 ± 0.26 | 1.05 ± 0.35 | 1.02 ± 0.33 | 0.95 ± 0.23 | 0.98 ± 0.19 | 0.97 ± 0.23 | 0.88 ± 0.25 | 0.90 ± 0.31 |
| Urea (mg/dL) | 37.83 ± 9.72 | 33.06 ± 12.92 | 34.94 ± 12.47 | 39.18 ± 0.26 | 44.71 ± 18.64 | 41.50 ± 10.60 | 32.71 ± 7.57 | 35.76 ± 7.29 | 35.07 ± 6.04 | 35.88 ± 5.19 | 33.78 ± 4.18 |
Characteristics of the bacteria identified and the antibiotics administered.
| Characteristics | n, % | Intravenous antibiotics third and fourth weeks | Oral antibiotics |
|---|---|---|---|
| Staphylococcus aureus or coagulase-negative staphylococci | 14 (78) | ||
| Methicillin-susceptible | 12 (67) | Ceftriaxone | Ciprofloxacin, clindamycin |
| Methicillin-resistant | 2 (11) | Vancomycin. When allergy daptomycin | Ciprofloxacin, trimethoprim–sulfamethoxazole |
| Streptococcus species (except Streptococcus agalactiae) | 3 (17) | Ceftriaxone | Amoxicillin |
| Enterococcus species (penicillin-susceptible) and Streptococcus agalactiae | 1 (6) | Piperacillin/tazobactam, ampicillin/sulbactam | Amoxicillin |
| Enterobacteriaceae (quinolone-susceptible) | 4 (22) | Cefepime | Ciprofloxacin |
| Nonfermenters (e.g., | 2 (11) | Cefepime | Ciprofloxacin |
| Anaerobes | 0 | – | – |
| Fungal | 1 (6) | Fluconazole | Fluconazole |
Characteristics of the implant and radiography prior to revision surgery.
| Characteristics | n, % |
|---|---|
| Acetabular component | |
| Cemented | 11 (61) |
| Cementless | 7 (39) |
| Femoral component | |
| Cemented | 13 (72) |
| Cementless | 5 (28) |
| Acetabular component radiolucency | |
| Yes | 13 (72) |
| No | 5 (28) |
| Femoral component radiolucency | |
| Yes | 10 (56) |
| No | 8 (44) |
| Presence of acetabular component movement | |
| Yes | 10 (56) |
| No | 8 (44) |
| Presence of femoral component movement | |
| Yes | 4 (22) |
| No | 14 (78) |
Figure 3.Preoperative image exams: a left hip X-ray demonstrating a loose cemented acetabular component medially migrated, as well as the dislocation of the arthroplasty with ascension of the greater trochanter and femur. An acetabular defect classified as type III (combined defect: cavitary and segmental defect) according to AAOS. (A) anteroposterior X-ray and (B) profile/sagittal X-ray.
AAOS indicates American Academy of Orthopedic Surgeons Classification.
Figure 5.Sixty-four months postoperative image exams: (A) demonstrating the total osseointegration of the lyophilized bovine xenograft with the host bone. No radiolucency lines and no acetabular movement/migration are observed and (B) demonstrating that the osteotomy is completely consolidated and the long cementless distal fixation femoral component shows no movement/migration.
Figure 6.CRP and ESR values throughout the treatment: (A) the graph demonstrated CRP levels along with the treatment in the follow-up times. The first postoperative week and the other averages in the subsequent times: first to second week a decreased of 6.077 ± 1.362 mg/dL of CRP value, first to third week 7.379 ± 1.620 mg/dL, first to fourth 7.192 ± 1.290 mg/dL, first to eighth 7.820 ± 1.516 mg/dL, first to 16th 8.638 ± 1.387 mg/dL, first to 24th 8.0321 ± 1.697 mg/dL, first to 48th 9.515 ± 1.567 mg/dL, first to 72nd 9.385 ± 1.485 mg/dL, and first to the 96th week a decrease of 9.677 ± 1.552 mg/dL of CRP and (B) decrease in ESR values was observed only after the third week of follow-up: third to fourth week a decrease means of 12.412 ± 4.691 mm/hr, third to eighth week 22.798 ± 5.806 mm/hr, third to 16th 26.902 ± 6.069 mm/hr, third to 24th 29.902 ± 4.857 mm/hr, third to 48th 39.307 ± 4.445 mm/hr, third to 72nd 36.550 ± 5.449 mm/hr and third to the 96th a decrease means of 39.807 ± 5.406 mm/hr ESR value.
CRP indicates C-reactive protein; ESR, erythrocyte sedimentation rate.
Figure 7.Kaplan–Meier curves for survival e cumulative risk: (A) an overall survival of 78.31 ± 6.34 (65.89-90.74) (mean ± standard error [95% confidence interval]) months (89%) and (B) the cumulative risk of failure of one-stage revision surgery found in our study was 0.09 ± 0.03 (−0.3 to 0.47) months (12%).
Multivariate analysis of risk factors for one-stage revision surgery failure.
| Variables | Crude HR (95% CI) | Crude | Adjusted HR (95% CI) | Adjusted |
|---|---|---|---|---|
| Age | 1.02 (0.876-1.182) | .818 | – | – |
| Blood culture before surgery | 6.12 (0.38-99.31) | .202 | – | – |
|
| 16.49 (1.031-263.757) | .048 | 4.47 (0.279-71.808) | .029 |
| Culture results | ||||
| Gram positive | Reference | – | – | |
| Gram-negative | 30.14 (0.00-349 694 569) | .682 | – | – |
| Gram-positive and -negative | 1.00 (0.00-1.20E) | 1.00 | – | – |
| Sex | ||||
| Female | Reference | – | – | |
| Male | 39.44 (0.00-7 819 042.99) | .555 | – | – |
| Previous antibiotic use | 0.04 (0.00-7 884 228.0) | .743 | – | – |
| Previous diseases | ||||
| Systemic arterial hypertension | 34.22 (0.00-14 513 356.2) | .593 | – | – |
| Ischemic heart disease | 6.12 (0.38-99.31) | .202 | – | – |
| Diabetes | 398.37 (0.00-4.750E) | .471 | – | – |
| Ischemic cerebrovascular accident | 7.75 (0.484-123.88) | .148 | – | – |
| Kidney disease | 0.06 (0.00-1.46E) | .819 | – | – |
| Lung disease (COPD) | 2.91 (0.181-46.675) | .451 | – | – |
| Three-phase bone scintigraphy | 6.91 (0.81-591.432) | .394 | – | – |
| Social factors | ||||
| Smoking | 0.03 (0.00-12 396.74) | .593 | – | – |
| Alcoholism | 0.05 (0.00-1.39E) | .846 | – | – |
| Symptoms that suggest infection | ||||
| Sinus tract | 203.30 (0.00-143 614 283) | .032 | 135 461.00 (0.00-2.437E) | .958 |
| Persistent drainage | 90.92 (0.001-9 801 678.03) | .446 | – | – |
| Hyperemia | 128.06 (0.001-24 972 255.8) | .435 | – | – |
| Pruritus | 1 059 959.59 (0.00-8.157E) | .947 | – | – |
| Swelling | 134.03 (0.001-2697.8) | .435 | – | – |
| Material used in revision surgery | ||||
| Cemented acetabular component | Reference | – | – | |
| Cementless acetabular component | 5.72 (0.352-92.688) | .220 | – | – |
| Cemented femoral component | Reference | – | – | |
| Cementless femoral component | 24.19 (0.00-4.612E) | .743 | – | – |
| Lyophilized bovine xenograft | 0.84 (0.053-13.495) | .904 | – | – |
| Tantalum augmentation | 2.10 (0.131-33.562) | .601 | – | – |
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.